No significant strengths identified
| Name | Market Cap | Current Price | P/E Ratio | Revenue Growth 1Y | Net Margin | ROE | FCF Yield | Debt/Equity |
|---|---|---|---|---|---|---|---|---|
| RDGTRidgetech Inc. | 43.15M | 2.36 | 1.28 | -22.37% | -8.97% | -134.46% | 1.47% | 0.35 |
| WGRXWellgistics Health, Inc. | 41.73M | 0.41 | -3.14 | -13% | -10.78% | 3.73 |
| Dec 2023 | Dec 2024 | |
|---|---|---|
| Sales/Revenue | 0 | 18.13M |
| Revenue Growth % | - | - |
| Cost of Goods Sold | 0 | 16.36M |
| COGS % of Revenue | - | 0.9% |
| Gross Profit | 0 | 1.77M |
| Gross Margin % | - | 0.1% |
| Gross Profit Growth % | - | - |
| Operating Expenses | 2.88M | 7.91M |
| OpEx % of Revenue | - | 0.44% |
| Selling, General & Admin | 2.88M | 6.8M |
| SG&A % of Revenue | - | 0.37% |
| Research & Development | 375 | 0 |
| R&D % of Revenue | - | - |
| Other Operating Expenses | -375 | 1.11M |
| Operating Income | -2.88M | -6.15M |
| Operating Margin % | - | -0.34% |
| Operating Income Growth % | - | -1.13% |
| EBITDA | -2.88M | -5.03M |
| EBITDA Margin % | - | -0.28% |
| EBITDA Growth % | - | -0.75% |
| D&A (Non-Cash Add-back) | 0 | 1.11M |
| EBIT | -2.88M | -6.02M |
| Net Interest Income | -15.08K | -831.47K |
| Interest Income | 0 | 0 |
| Interest Expense | 15.08K | 831.47K |
| Other Income/Expense | -15.08K | -711.09K |
| Pretax Income | -2.9M | -6.86M |
| Pretax Margin % | - | -0.38% |
| Income Tax | 0 | 0 |
| Effective Tax Rate % | 1% | 1% |
| Net Income | -2.9M | -6.86M |
| Net Margin % | - | -0.38% |
| Net Income Growth % | - | -1.37% |
| Net Income (Continuing) | -2.9M | -6.86M |
| Discontinued Operations | 0 | 0 |
| Minority Interest | 0 | 0 |
| EPS (Diluted) | -0.06 | -0.13 |
| EPS Growth % | - | -1.17% |
| EPS (Basic) | -0.06 | -0.13 |
| Diluted Shares Outstanding | 44.72M | 51.94M |
| Basic Shares Outstanding | 44.72M | 51.94M |
| Dividend Payout Ratio | - | - |
| Dec 2023 | Dec 2024 | |
|---|---|---|
| Total Current Assets | 338.36K | 15.17M |
| Cash & Short-Term Investments | 1.36K | 1.03M |
| Cash Only | 1.36K | 1.03M |
| Short-Term Investments | 0 | 0 |
| Accounts Receivable | 337K | 3.75M |
| Days Sales Outstanding | - | 75.42 |
| Inventory | 0 | 9.52M |
| Days Inventory Outstanding | - | 212.35 |
| Other Current Assets | 0 | 875.39K |
| Total Non-Current Assets | 0 | 42.16M |
| Property, Plant & Equipment | 0 | 1.92M |
| Fixed Asset Turnover | - | 9.46x |
| Goodwill | 0 | 16.22M |
| Intangible Assets | 0 | 22.36M |
| Long-Term Investments | 0 | 17.67K |
| Other Non-Current Assets | 0 | 1.65M |
| Total Assets | 338.36K | 57.33M |
| Asset Turnover | - | 0.32x |
| Asset Growth % | - | 168.44% |
| Total Current Liabilities | 2.89M | 38.05M |
| Accounts Payable | 1.04M | 6.33M |
| Days Payables Outstanding | - | 141.31 |
| Short-Term Debt | 350K | 12.04M |
| Deferred Revenue (Current) | 0 | 245.76K |
| Other Current Liabilities | 950K | 3.11M |
| Current Ratio | 0.12x | 0.40x |
| Quick Ratio | 0.12x | 0.15x |
| Cash Conversion Cycle | - | 146.46 |
| Total Non-Current Liabilities | 350K | 12.55M |
| Long-Term Debt | 350K | 11.46M |
| Capital Lease Obligations | 0 | 1.1M |
| Deferred Tax Liabilities | 0 | 0 |
| Other Non-Current Liabilities | 0 | 0 |
| Total Liabilities | 3.24M | 50.6M |
| Total Debt | 700K | 25.11M |
| Net Debt | 698.64K | 24.08M |
| Debt / Equity | - | 3.73x |
| Debt / EBITDA | - | - |
| Net Debt / EBITDA | - | - |
| Interest Coverage | -191.01x | -7.39x |
| Total Equity | -2.9M | 6.73M |
| Equity Growth % | - | 3.32% |
| Book Value per Share | -0.06 | 0.13 |
| Total Shareholders' Equity | -2.9M | 6.73M |
| Common Stock | 4.47K | 5.11K |
| Retained Earnings | -2.9M | -9.76M |
| Treasury Stock | 0 | 0 |
| Accumulated OCI | 0 | 0 |
| Minority Interest | 0 | 0 |
| Dec 2023 | Dec 2024 | |
|---|---|---|
| Cash from Operations | -349.14K | -1.22M |
| Operating CF Margin % | - | -0.07% |
| Operating CF Growth % | - | -2.51% |
| Net Income | -2.9M | -6.86M |
| Depreciation & Amortization | 0 | 1.11M |
| Stock-Based Compensation | 0 | 1.08M |
| Deferred Taxes | 0 | 0 |
| Other Non-Cash Items | 0 | 93.38K |
| Working Capital Changes | 2.55M | 3.34M |
| Change in Receivables | 0 | -40.08K |
| Change in Inventory | 0 | -72.36K |
| Change in Payables | 1.03M | -882.32K |
| Cash from Investing | 0 | 469.07K |
| Capital Expenditures | 0 | -377.29K |
| CapEx % of Revenue | - | 0.02% |
| Acquisitions | - | - |
| Investments | - | - |
| Other Investing | 0 | -85.01K |
| Cash from Financing | 350.5K | 1.78M |
| Debt Issued (Net) | - | - |
| Equity Issued (Net) | - | - |
| Dividends Paid | 0 | 0 |
| Share Repurchases | - | - |
| Other Financing | 0 | 1.15M |
| Net Change in Cash | - | - |
| Free Cash Flow | -349.14K | -1.6M |
| FCF Margin % | - | -0.09% |
| FCF Growth % | - | -3.59% |
| FCF per Share | -0.01 | -0.03 |
| FCF Conversion (FCF/Net Income) | 0.12x | 0.18x |
| Interest Paid | 0 | 0 |
| Taxes Paid | 0 | 0 |
| Metric | 2023 | 2024 |
|---|---|---|
| Return on Equity (ROE) | - | -357.65% |
| Return on Invested Capital (ROIC) | - | -32.21% |
| Gross Margin | - | 9.75% |
| Net Margin | - | -37.82% |
| Debt / Equity | - | 3.73x |
| Interest Coverage | -191.01x | -7.39x |
| FCF Conversion | 0.12x | 0.18x |
| 2024 | |
|---|---|
| Product | 17.67M |
| Product Growth | - |
Wellgistics Health, Inc. (WGRX) reported $5.6M in revenue for fiscal year 2024.
Wellgistics Health, Inc. (WGRX) grew revenue by 0.0% over the past year. Growth has been modest.
Wellgistics Health, Inc. (WGRX) reported a net loss of $73.1M for fiscal year 2024.
Wellgistics Health, Inc. (WGRX) has a return on equity (ROE) of -357.7%. Negative ROE indicates the company is unprofitable.
Wellgistics Health, Inc. (WGRX) had negative free cash flow of $7.3M in fiscal year 2024, likely due to heavy capital investments.